SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

Search

Almirall SA

Fermé

SecteurSoins de santé

12.68 -1.25

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.62

Max

12.7

Chiffres clés

By Trading Economics

Revenu

-1.4M

20M

Ventes

287M

548M

P/E

Moyenne du Secteur

58.364

60.328

Rendement du dividende

1.49

Marge bénéficiaire

3.575

Employés

2,108

EBITDA

36M

102M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+9.81% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.49%

2.24%

Prochains Résultats

11 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

121M

2.8B

Ouverture précédente

13.93

Clôture précédente

12.68

Score Technique

By Trading Central

Confiance

Bearish Evidence

Almirall SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2026, 19:19 UTC

Acquisitions, Fusions, Rachats

Intertek Group Rejects EQT's Revised Offer

24 avr. 2026, 23:37 UTC

Acquisitions, Fusions, Rachats

Scoring the Cook Era -- Barrons.com

24 avr. 2026, 20:51 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 20:50 UTC

Market Talk
Principaux Événements d'Actualité

Financial Services Roundup: Market Talk

24 avr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 avr. 2026, 20:39 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 20:09 UTC

Résultats

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 avr. 2026, 19:48 UTC

Market Talk
Principaux Événements d'Actualité

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 avr. 2026, 19:25 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 19:25 UTC

Acquisitions, Fusions, Rachats

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 avr. 2026, 19:22 UTC

Résultats

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 avr. 2026, 19:06 UTC

Résultats

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 avr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 avr. 2026, 18:30 UTC

Acquisitions, Fusions, Rachats

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 avr. 2026, 18:28 UTC

Acquisitions, Fusions, Rachats

Intertek Rejects Revised EQT Offer

24 avr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 avr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 avr. 2026, 17:42 UTC

Résultats

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 avr. 2026, 17:28 UTC

Résultats

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 avr. 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 avr. 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24 avr. 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 avr. 2026, 17:09 UTC

Market Talk
Résultats

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 avr. 2026, 17:09 UTC

Acquisitions, Fusions, Rachats

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 avr. 2026, 17:06 UTC

Résultats
Acquisitions, Fusions, Rachats

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 avr. 2026, 16:51 UTC

Résultats
Acquisitions, Fusions, Rachats

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 avr. 2026, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

24 avr. 2026, 16:20 UTC

Market Talk
Principaux Événements d'Actualité

Financial Services Roundup: Market Talk

24 avr. 2026, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

24 avr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparaison

Variation de prix

Almirall SA prévision

Objectif de Prix

By TipRanks

9.81% hausse

Prévisions sur 12 Mois

Moyen 14.1 EUR  9.81%

Haut 14.2 EUR

Bas 14 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

9.76 / 10.2Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Strong Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
help-icon Live chat